Use of cardioprotective glucose lowering therapy before and after myocardial infarction among patients with type-2 diabetes: a nationwide registry study
Progressive disease substrate in obese type 2 diabetic patients with coronary artery disease despite achieving HbA1c <7.0%: sub-analysis from the OPTIMAL randomized study